Gene expression profiles of phaeochromocytomas with ERBB2 overexpression reveal a new molecular mechanism tumourigenicity

Clinical Endocrinology

Volumn 77, Issue 3, 2012, Pages 399-406

  Qi, Yan ^a   Su, Tingwei ^a   Zhang, Xia ^a   Jiang, Yiran ^a   Yuan, Wenqi ^a   Wang, Weiqing ^a   Cui, Bin ^a   Ning, Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PARAGANGLIOMA; PHEOCHROMOCYTOMA; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84865042447     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04388.x     Document Type: Article

References (45)

1. Lenders, J.W., Eisenhofer, G., Mannelli, M., et al,. (2005) Phaeochromocytoma. Lancet, 66, 665-675.
2. Dluhy, R.G., (2002) Phaeochromocytoma-death of an axiom. New England Journal of Medicine, 346, 1486-1488.
3. Elder, E.E., Xu, D., Hoog, A., et al,. (2003) KI-67 AND hTERT expression can aid in the distinction between malignant and benign phaeochromocytoma and paraganglioma. Modern Pathology, 16, 246-255.
4. Harari, A., &, Inabnet 3rd, W.B., (2011) Malignant phaeochromocytoma: a review. American Journal of Surgical 201, 700-708.
5. Ayala-Ramirez, M., Feng, L., Johnson, M.M., et al,. (2011) Clinical risk factors for malignancy and overall survival in patients with phaeochromocytomas and sympathetic paragangliomas: primary tumour size and primary tumour location as prognostic indicators. Journal of Clinical Endocrinology and Metabolism, 96, 717-725.
6. Chrisoulidou, A., Kaltsas, G., Ilias, I., et al,. (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocrine-Related Cancers, 14, 569-585.
7. Eisenhofer, G., Bornstein, S.R., Brouwers, F.M., et al,. (2004) Malignant phaeochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancers, 11, 423-436.
8. Yarden, Y., &, Sliwkowski, M.X., (2001) Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2, 127-137.
9. Citri, A., &, Yarden, Y., (2006) EGF-ERBB signalling: towards the systems level. Nature Reviews Molecular Cell Biology, 7, 505-516.
10. Slamon, D.J., Clark, G.M., Wong, S.G., et al,. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.
11. Ross, J.S., &, Fletcher, J.A., (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells, 16, 413-428.
12. Slamon, D.J., Godolphin, W., Jones, L.A., et al,. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712.
13. Koeppen, H.K., Wright, B.D., Burt, A.D., et al,. (2001) Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology, 38, 96-104.
14. Yano, T., Doi, T., Ohtsu, A., et al,. (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncology Reports, 15, 65-71.
15. Mimura, K., Kono, K., Hanawa, M., et al,. (2005) Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. British Journal of Cancer, 92, 1253-1260.
16. Morrison, C., Zanagnolo, V., Ramirez, N., et al,. (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. Journal of Clinical Oncology, 24, 2376-2385.
17. Press, M.F., Bernstein, L., Thomas, P.A., et al,. (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. Journal of Clinical Oncology, 15, 2894-2904.
18. Hogdall, E.V., Christensen, L., Kjaer, S.K., et al,. (2003) Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer, 98, 66-73.
19. de Krijger, R.R., van der Harst, E., van der Ham, F., et al,. (1999) Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. Journal of Pathology, 188, 51-55.
20. Saeger, W., Fassnacht, M., Reincke, M., et al,. (2002) Expression of HER-2/neu receptor protein in adrenal tumours. Pathology-Research and Practice, 198, 445-448.
21. Castilla-Guerra, L., Moreno, A.M., Fernandez-Moreno, M.C., et al,. (1997) Expression and prognostic value of c-erbB-2 oncogene product in human phaeochromocytomas. Histopathology, 31, 144-149.
22. Tavangar, S.M., Shojaee, A., Moradi Tabriz, H., et al,. (2010) Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant phaeochromocytoma. Pathology-Research and Practice, 206, 305-309.
23. Yuan, W., Wang, W., Cui, B., et al,. (2008) Overexpression of ERBB-2 was more frequently detected in malignant than benign phaeochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocrine-Related Cancers, 15, 343-350.
24. Mittendorf, E.A., Evans, D.B., et al,. (2007) Phaeochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematology/Oncology Clinics of North America, 21, 509-525.
25. Favier, J., Igaz, P., Burnichon, N., et al,. (2012) Rationale for anti-angiogenic therapy in phaeochromocytoma and paraganglioma. Endocrine Pathology 23, 34-42.
26. Fuller, T.F., Ghazalpour, A., Aten, J.E., et al,. (2007) Weighted gene coexpression network analysis strategies applied to mouse weight. Mammalian Genome, 18, 463-472.
27. Ashburner, M., Ball, C.A., Blake, J.A., et al,. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature Genetics, 25, 25-29.
28. Gene Ontology Consortium. (2006) The gene ontology (GO) project in 2006. Nucleic Acids Research 34, D322-D326.
29. Ogata, H., Goto, S., Sato, K., et al,. (1999) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Research, 27, 29-34.
30. Yi, M., Horton, J.D., Cohen, J.C., et al,. (2006) WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics, 7, 30.
31. Schaller, M.D., Hildebrand, J.D., Shannon, J.D., et al,. (1994) Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Molecular and Cellular Biology, 14, 1680-1688.
32. Waldmann, J., Fendrich, V., Holler, J., et al,. (2010) Microarray analysis reveals differential expression of benign and malignant phaeochromocytoma. Endocrine-Related Cancers, 17, 743-756.
33. Brouwers, F.M., Elkahloun, A.G., Munson, P.J., et al,. (2006) Gene expression profiling of benign and malignant phaeochromocytoma. Annals of the New York Academy of Sciences, 1073, 541-556.
34. Summy, J.M., &, Gallick, G.E., (2003) Src family kinases in tumour progression and metastasis. Cancer and Metastasis Reviews 22, 337-358.
35. Gabarra-Niecko, V., Schaller, M.D., &, Dunty, J.M., (2003) FAK regulates biological processes important for the pathogenesis of cancer. Cancer and Metastasis Reviews 22, 359-374.
36. Zhao, J., &, Guan, J.L., (2009) Signal transduction by focal adhesion kinase in cancer. Cancer and Metastasis Reviews 28, 35-49.
37. Benlimame, N., He, Q., Jie, S., et al,. (2005) FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. Journal of Cell Biology, 171, 505-516.
38. Xu, Y., Benlimame, N., Su, J., et al,. (2009) Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells. British Journal of Cancer, 100, 633-643.
39. Parsons, J.T., (2003) Focal adhesion kinase: the first ten years. Journal of Cell Science 116, 1409-1416.
40. Schlaepfer, D.D., Jones, K.C., &, Hunter, T., (1998) Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events. Molecular Cell Biology 18, 2571-2585.
41. Westhoff, M.A., Serrels, B., Fincham, V.J., et al,. (2004) SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Molecular Cell Biology, 24, 8113-8133.
42. Romond, E.H., Perez, E.A., Bryant, J., et al,. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353, 1673-1684.
43. Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., et al,. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine, 353, 1659-1672.
44. Hudis, C.A., (2007) Trastuzumab-mechanism of action and use in clinical practice. New England Journal of Medicine, 357, 39-51.
45. Sworczak, K., Zaczek, A., Babinska, A., et al,. (2002) Gene copy numbers of erbB oncogenes in human phaeochromocytoma. Oncology Reports, 9, 1373-1378.